Evaluation of a fibrin-binding gadolinium chelate peptide tetramer in a brain glioma model

Investigative Radiology

Volumn 46, Issue 3, 2011, Pages 169-177

  Morelli, John N ^a   Runge, Val M ^b   Williams, Jonathon M ^a   Beissner, Robert S ^a   Tweedle, Michael ^c  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

brain; gadolinium chelate; magnetic resonance imaging; neoplasm; rat

Indexed keywords

EP 2104R; FIBRIN; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; GLIOMA; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO; TUMOR DIAGNOSIS;

EID: 79751526718     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181f7a0b0     Document Type: Article

References (42)

1. Wintersperger BJ, Runge VM, Biswas J, et al. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques. Invest Radiol. 2007;42:558-563. (Pubitemid 47051832)
2. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol. 2006;41:244-248. (Pubitemid 44406184)
3. Noebauer-Huhmann IM, Pinker K, Barth M, et al. Contrast-enhanced, high-resolution, susceptibility-weighted magnetic resonance imaging of the brain: dose-dependent optimization at 3 tesla and 1.5 tesla in healthy volunteers. Invest Radiol. 2006;41:249-255. (Pubitemid 44406185)
4. Biswas J, Nelson CB, Runge VM, et al. Brain tumor enhancement in magnetic resonance imaging: comparison of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 tesla. Invest Radiol. 2005;40: 792-797. (Pubitemid 41690437)
5. Runge VM, Clanton JA, Price AC, et al. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magn Reson Imaging. 1985;3:43-55. (Pubitemid 15075062)
6. Kim HJ, Pyeun YS, Kim YW, et al. A model for research on the blood-brain barrier disruption induced by unsaturated fatty acid emulsion. Invest Radiol. 2005;40:270-276. (Pubitemid 40571682)
7. Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging. 2007;25:884-899.
8. Gohr-Rosenthal S, Schmitt-Willich H, Ebert W, et al. The demonstration of human tumors on nude mice using gadolinium-labelled monoclonal antibodies for magnetic resonance imaging. Invest Radiol. 1993;28:789-795. (Pubitemid 24079727)
9. Anderson SA, Lee KK, Frank JA. Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. Invest Radiol. 2006;41:332-338. (Pubitemid 44406195)
10. Chapon C, Franconi F, Lemaire L, et al. High field magnetic resonance imaging evaluation of superparamagnetic iron oxide nanoparticles in a permanent rat myocardial infarction. Invest Radiol. 2003;38:141-146. (Pubitemid 36255284)
11. Clement O, Guimaraes R, de Kerviler E, et al. Magnetic resonance lymphography. Enhancement patterns using superparamagnetic nanoparticles. Invest Radiol. 1994;29(suppl 2):S226-S228. (Pubitemid 24221116)
12. Curtet C, Maton F, Havet T, et al. Polylysine-Gd-DTPAn and polylysine-Gd-DOTAn coupled to anti-CEA F(ab')2 fragments as potential immunocontrast agents. Relaxometry, biodistribution, and magnetic resonance imaging in nude mice grafted with human colorectal carcinoma. Invest Radiol. 1998;33: 752-761
13. Flacke S, Fischer S, Scott MJ, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation. 2001;104:1280-1285. (Pubitemid 32848118)
14. Zhu D, Lu X, Hardy PA, et al. Nanotemplate-engineered nanoparticles containing gadolinium for magnetic resonance imaging of tumors. Invest Radiol. 2008;43:129-140.
15. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol. 2007;42:139-145. (Pubitemid 46104895)
16. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
17. Ayyagari AL, Zhang X, Ghaghada KB, et al. Long-circulating liposomal contrast agents for magnetic resonance imaging. Magn Reson Med. 2006;55: 1023-1029.
18. Vymazal J, Spuentrup E, Cardenas-Molina G, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol. 2009;44:697-704.
19. Spuentrup E, Botnar RM, Wiethoff AJ, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol. 2008;18:1995-2005.
20. Bardos H, Molnar P, Csecsei G, et al. Fibrin deposition in primary and metastatic human brain tumours. Blood Coagul Fibrinolysis. 1996;7:536-548. (Pubitemid 26294883)
21. Dvorak HF, Senger DR, Dvorak AM, et al. Regulation of extravascular coagulation by microvascular permeability. Science. 1985;227:1059-1061. (Pubitemid 15142051)
22. Neri D, Carnemolla B, Nissim A, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol. 1997;15:1271-1275. (Pubitemid 27465138)
23. Stenman S, Vaheri A. Fibronectin in human solid tumors. Int J Cancer. 1981;27:427-435. (Pubitemid 11159727)
24. Overoye-Chan K, Koerner S, Looby RJ, et al. EP-2104R: a fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. J Am Chem Soc. 2008;130:6025-6039. (Pubitemid 351620850)
25. Runge VM, Jacobson S, Wood ML, et al. MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA. Radiology. 1988;166:835-838. (Pubitemid 18058952)
26. Fries P, Runge VM, Bucker A, et al. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relax-ivity macromolecular contrast media with a standard extracellular Gd-chelate in a rat brain tumor model. Invest Radiol. 2009;44:200-206.
27. Attenberger UI, Runge VM, Jackson CB, et al. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Invest Radiol. 2009;44:251-256.
28. Wintersperger BJ, Runge VM, Tweedle MF, et al. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. Invest Radiol. 2009;44:89-94.
29. Spuentrup E, Katoh M, Wiethoff AJ, et al. Molecular coronary MR imaging of human thrombi using EP-2104R, a fibrintargeted contrast agent: experimental study in a swine model. Rofo. 2007;179:1166-1173. (Pubitemid 350155124)
30. Katoh M, Haage P, Wiethoff AJ, et al. Molecular magnetic resonance imaging of deep vein thrombosis using a fibrintargeted contrast agent: a feasibility study. Invest Radiol. 2009;44:146-150.
31. Spuentrup E, Katoh M, Buecker A, et al. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol. 2007;42:586-595. (Pubitemid 47051836)
32. Stracke CP, Katoh M, Wiethoff AJ, et al. Molecular MRI of cerebral venous sinus thrombosis using a new fibrin-specific MR contrast agent. Stroke. 2007;38:1476-1481. (Pubitemid 46684148)
33. Spuentrup E, Buecker A, Katoh M, et al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrintargeted contrast agent. Circulation. 2005;111:1377-1382. (Pubitemid 40396803)
34. Uppal R, Medarova Z, Farrar CT, et al. Molecular imaging of fibrin in a mouse tumor model. Proc World Mol Imaging Congr. 2010:2337.
35. Uppal R, Medarova Z, Farrar C, et al. Molecular MR imaging of fibrin in tumors [abstract 1250]. Proc Intl Soc Magn Reson Med. 2009.
36. Weinmann HJ, Ebert W, Misselwitz B, et al. Tissue-specific MR contrast agents. Eur J Radiol. 2003;46:33-44. (Pubitemid 36332077)
37. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724. (Pubitemid 41546838)
38. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol. 2006;41:206-212. (Pubitemid 44406180)
39. Botnar RM, Perez AS, Witte S, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation. 2004;109:2023-2029. (Pubitemid 38544494)
40. Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol. 2009;44:433-439.
41. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74-81.
42. Le Duc G, Corde S, Charvet AM, et al. In vivo measurement of gadolinium concentration in a rat glioma model by monochromatic quantitative computed tomography: comparison between gadopentetate dimeglumine and gadobu-trol. Invest Radiol. 2004;39:385-393. (Pubitemid 38802813)